Literature DB >> 2153093

Absence of growth-hormone receptor in hepatocellular carcinoma and cirrhotic liver.

T C Chang1, J J Lin, S C Yu, T J Chang.   

Abstract

Hepatocellular carcinoma is a hormone-sensitive tumor. It has been reported that thyroxine and prolactin significantly stimulated hepatoma growth, whereas growth hormone failed to do so. To learn whether the growth hormone receptor is present in human hepatocellular carcinoma, we used radioreceptor assays in samples of human hepatocellular carcinoma. The liver tissues adjacent to hepatocellular carcinoma (mostly cirrhotic) and control liver tissues (taken during various surgical procedures) were also studied. The study results showed that the affinity constant and capacity of high-affinity growth hormone receptor in normal liver tissues were 6.6 +/- 2.0 x 10(10) mol/L-1 (mean +/- SE, n = 7) and 20.7 +/- 11.5 fmol/mg protein, respectively. The affinity constant and capacity of low-affinity growth hormone receptor in normal liver tissues were 8.9 +/- 3.3 x 10(9) mol/L-1 and 64.7 +/- 32.1 fmol/mg protein, respectively. The absence of growth hormone receptor in human hepatocellular carcinoma and cirrhotic liver samples may explain the absence of growth hormone in the stimulation of hepatoma growth and the decrease of somatomedin levels in cirrhosis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2153093     DOI: 10.1002/hep.1840110121

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  9 in total

1.  Expression of growth hormone receptor and its mRNA in hepatic cirrhosis.

Authors:  Hong-Tao Wang; Shuang Chen; Jie Wang; Qing-Jia Ou; Chao Liu; Shu-Sen Zheng; Mei-Hai Deng; Xiao-Ping Liu
Journal:  World J Gastroenterol       Date:  2003-04       Impact factor: 5.742

2.  Decreased IGF-I bioavailability after ethanol abuse in alcoholics: partial restitution after short-term abstinence.

Authors:  S Röjdmark; K Brismar
Journal:  J Endocrinol Invest       Date:  2001 Jul-Aug       Impact factor: 4.256

3.  Protective effects of recombinant human growth hormone on cirrhotic rats.

Authors:  Shuang Chen; Hong-Tao Wang; Bin Yang; Yu-Ru Fu; Qing-Jia Ou
Journal:  World J Gastroenterol       Date:  2004-10-01       Impact factor: 5.742

Review 4.  Human conditions of insulin-like growth factor-I (IGF-I) deficiency.

Authors:  Juan E Puche; Inma Castilla-Cortázar
Journal:  J Transl Med       Date:  2012-11-14       Impact factor: 5.531

5.  Increased expression of growth hormone and prolactin receptors in hepatocellular carcinomas.

Authors:  T García-Caballero; H M Mertani; A Lambert; R Gallego; M Fraga; E Pintos; J Forteza; M Chevallier; P E Lobie; B K Vonderhaar; A Beiras; G Morel
Journal:  Endocrine       Date:  2000-06       Impact factor: 3.925

6.  IGF-1 decreases portal vein endotoxin via regulating intestinal tight junctions and plays a role in attenuating portal hypertension of cirrhotic rats.

Authors:  Tian-Yu Zhao; Li-Ping Su; Chun-Ye Ma; Xiao-Han Zhai; Zhi-Jun Duan; Ying Zhu; Gang Zhao; Chun-Yan Li; Li-Xia Wang; Dong Yang
Journal:  BMC Gastroenterol       Date:  2015-07-08       Impact factor: 3.067

Review 7.  Insulin-Like Growth Factor-1 Deficiency and Cirrhosis Establishment.

Authors:  Rocio G de la Garza; Luis Alonso Morales-Garza; Irene Martin-Estal; Inma Castilla-Cortazar
Journal:  J Clin Med Res       Date:  2017-02-21

8.  A survey of correlation between insulin-like growth factor-I (igf-I) levels and severity of liver cirrhosis.

Authors:  Asghar Khoshnood; Mohsen Nasiri Toosi; Mohammad Jafar Faravash; Alireza Esteghamati; Hosein Froutan; Hadi Ghofrani; Mohammad Kalani; Arash Miroliaee; Ahmad Abdollahi; Andrabi Yasir
Journal:  Hepat Mon       Date:  2013-02-23       Impact factor: 0.660

Review 9.  Type I insulin-like growth factor as a liver reserve assessment tool in hepatocellular carcinoma.

Authors:  Reham Abdel-Wahab; Samir Shehata; Manal M Hassan; Mouhammed A Habra; Ghazaleh Eskandari; Peggy T Tinkey; Jennifer Mitchell; Ju-Seog Lee; Hesham M Amin; Ahmed O Kaseb
Journal:  J Hepatocell Carcinoma       Date:  2015-09-18
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.